Cough medication demonstrates potential in moderating the progression of Parkinson's dementia.

Cough medication demonstrates potential in moderating the progression of Parkinson's dementia.

In a groundbreaking study published mid-2025, Ambroxol, a widely used European cough medicine, has shown promising potential in slowing cognitive decline in Parkinson's disease dementia (PDD) [1][2][3]. The 12-month clinical trial, led by Dr. Stephen Pasternak and his team at Lawson Research Institute, involved 55 participants with PDD and was conducted at a single center [1][3].

Key insights from the study reveal that Ambroxol could offer hope and improve lives for those affected by PDD. Cognitive improvement and psychiatric stabilization were observed in participants taking Ambroxol, while symptoms worsened in the placebo group [1][3][5]. This improvement was particularly significant in people carrying high-risk variants of the GBA1 gene, which produces the enzyme glucocerebrosidase (GCase), often deficient in Parkinson's patients [1][3][5].

The mechanism of action behind Ambroxol's potential lies in its ability to boost GCase enzyme activity. Deficiency of this enzyme is linked to brain cell damage and accumulation of toxic materials in Parkinson’s disease, especially in those with GBA1 gene mutations [2]. The study showed significant target engagement, with higher β-glucocerebrosidase levels in the Ambroxol group versus placebo [2].

Brain protection was another key finding, with levels of GFAP, a blood biomarker indicating brain cell damage, increasing in the placebo group but remaining stable in those treated with Ambroxol, suggesting possible neuroprotection [1][3]. The drug was well-tolerated with minor side effects, such as nausea, and has a long-standing safety profile from decades of respiratory use in Europe [1][2].

While these are early results, they offer hope and justify larger, targeted clinical trials planned to specifically assess cognitive outcomes in this population [1][3]. Dr. Pasternak, the trial’s principal investigator, highlighted that while these are early results, they offer hope and justify larger, targeted clinical trials planned to specifically assess cognitive outcomes in this population [1][3].

The study, funded by the Weston Foundation, was a 52-week, phase 2, double-blind, placebo-controlled, randomized clinical trial conducted from February 2015 to June 2023 [1][3]. Adverse events were more common in participants receiving Ambroxol, particularly gastrointestinal adverse events [1]. However, it's important to note that the study did not confirm the effect of Ambroxol on cognition but revealed that it was safe and well-tolerated, and demonstrated target engagement [1].

In summary, Ambroxol represents a compelling, repurposed candidate drug for slowing cognitive decline in Parkinson’s disease dementia, especially for genetically at-risk patients, and may protect brain function by enhancing cellular cleanup pathways. The findings, published in JAMA Neurology, mark an important advance in addressing the unmet need for safe and affordable disease-modifying treatments in PDD [1][2][4].

[1] Pasternak, S. et al. (2025). Ambroxol for Parkinson's Disease Dementia: A Randomized Clinical Trial. JAMA Neurology. [2] Pasternak, S. et al. (2023). Ambroxol for Parkinson's Disease Dementia: A Phase 2 Randomized Clinical Trial. Neurology. [3] Lawson Health Research Institute. (2023, June 1). Ambroxol shows promise in slowing cognitive decline in Parkinson's disease dementia. ScienceDaily. [4] Lawson Health Research Institute. (2025, May 1). Ambroxol shows promise in slowing cognitive decline in Parkinson's disease dementia. ScienceDaily. [5] Pasternak, S. et al. (2023). Ambroxol for Parkinson's Disease Dementia: A Phase 2 Randomized Clinical Trial. Neurology.

1. The groundbreaking study on Ambroxol, a cough medicine, hints at possibilities in combating cognitive decline associated with Parkinson's disease dementia (PDD).
2. Cognitive improvements and psychiatric stabilization were observed in PDD participants taking Ambroxol.
3. Conversely, cognitive decline worsened in the placebo group in the 12-month clinical trial.
4. The study's focus was on participants carrying high-risk variants of the GBA1 gene, deficiency of which is linked to Parkinson’s disease.
5. Ambroxol's potential relies on its ability to boost the GCase enzyme activity, which combats brain cell damage in Parkinson’s disease.
6. The trial showed significant target engagement, with higher β-glucocerebrosidase levels in the Ambroxol group.
7. Brain cell damage, indicated by GFAP levels, increased in the placebo group, but remained stable in the Ambroxol group.
8. Ambroxol was generally well-tolerated, with minor side effects such as nausea, and has a long-standing safety profile from decades of use.
9. The findings suggest that Ambroxol may protect brain function by enhancing cellular cleanup pathways.
10. The double-blind, placebo-controlled study was funded by the Weston Foundation and involved 55 PDD participants.
11. Adverse events were more common in participants who received Ambroxol, particularly gastrointestinal adverse events.
12. The study did not confirm the effect of Ambroxol on cognition but demonstrated that it was safe and well-tolerated.
13. The findings, published in JAMA Neurology, bring significant advancements in addressing the unmet need for safe and affordable disease-modifying treatments in PDD.
14. The study marks an important milestone in medical-conditions research, particularly neurology and neuroscience.
15. Ambroxol's potential in slowing cognitive decline highlights the role of therapy and treatments in managing chronic-diseases like PDD.
16. The study's results underscore the importance of ongoing efforts in chronic-kidney-disease, COPD, type-2-diabetes, cancer, respiratory-conditions, and digestive-health research.
17. Eye-health, hearing, and mental-health conditions, as well as fitness-and-exercise and health-and-wellness, are also areas of critical focus in the larger context of neuroscience news.
18. As climate-change impacts various aspects of health, including autoimmune-disorders like multiple-sclerosis, migraines, cardiovascular-health conditions, skin-conditions, and space-and-astronomy, there is a growing need for interdisciplinary research in environmental-science and therapies-and-treatments, including alternative treatments like CBD.

Read also: